@article{db82f18ce3be4a12bd8164707c52c5e1,
title = "Diversifying preclinical research tools: expanding patient-derived models to address cancer health disparities",
abstract = "Cancer health disparities define a critical healthcare issue for racial/ethnic minorities in the USA. Key findings have led to cancer treatment improvements tailored to minority patients, but such successes have been rare. Here, we highlight how the use of patient-derived xenograft (PDX) and organoid models could resolve current blocks toward precision cancer health equity.",
author = "Halmai, {Nicole B.} and Carvajal-Carmona, {Luis G.}",
note = "Funding Information: We are grateful to Ana Estrada for her critical review of the manuscript. We are also grateful to the National Institutes of Health (NCI Grants R01CA223978 , U54CA233306 , U54CA233306-1S2 , and P30CA093373 and to the Auburn Community Cancer Endowed Chair in Basic Science for funding our cancer health disparity research studies. The opinions expressed in this article are the authors{\textquoteright} own and do not reflect the view of the National Institutes of Health. Funding Information: Initiatives to apply PDXs and PDOs within the context of cancer health disparities are underway, including efforts supported by the NCI's PDX Development and Trial Centers (PDTCs) Research Network, with two PDTCs exclusively focused on racial/ethnic minority PDX generation [12,13]. Centralized and accessible minority patient-derived models and genomic data will help to further our understanding of the factors driving increased cancer burdens among minority populations and provide a model library to elucidate distinct mechanisms of treatment response and resistance in minority patients with cancer (Figure 2). These discoveries will help to answer critical questions related to cancer precision medicine and disparities: are we missing cancer subtypes that are unique to minority populations? Are there unique genetic alterations that can be more effectively targeted with therapeutic combinations in minority patients other than current standard-of-care treatment? Can we identify minority patient populations that would benefit from targeted early-detection or preventative screening for cancer types that are relatively less common in the general population? This last question is particularly pertinent for gastric cancer, which is highly treatable if diagnosed in early stages but does not rank among the top-12 most common cancer types in the USA.We are grateful to Ana Estrada for her critical review of the manuscript. We are also grateful to the National Institutes of Health (NCI Grants R01CA223978, U54CA233306, U54CA233306-1S2, and P30CA093373 and to the Auburn Community Cancer Endowed Chair in Basic Science for funding our cancer health disparity research studies. The opinions expressed in this article are the authors? own and do not reflect the view of the National Institutes of Health. None declared by authors. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
doi = "10.1016/j.trecan.2022.01.007",
language = "English (US)",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
}